Tesamorelin 20mg
Tesamorelin research pack containing 10 vials, each labeled at a nominal 20 mg, for a nominal 200 mg across the complete pack. The amounts are catalog declarations rather than assay results. For research use only (RUO); not for human or veterinary use.
Out of stock
Tesamorelin 20mg/vial, 10 vials Product Description
Tesamorelin is described in the literature as a 44-amino-acid analogue of growth-hormone-releasing factor. That literature identity does not independently verify the sequence, salt form, termini, excipients, or composition of this catalog material. The sale unit is ten separate vials. Each vial is nominally 20 mg, making the arithmetic pack total 200 mg; neither figure is a concentration or an independently measured result. The physical count and the per-vial amount must remain visible together.
It is therefore related rather than exact and cannot validate Lobo's strength, pack configuration, documentation, or lot attributes.
Scientific context may describe receptor-axis assays, controlled physiology studies, imaging methods, and predefined biomarker analyses reported for characterized tesamorelin materials. This catalog entry provides no protocol, clinical interpretation, or expected outcome for the supplied pack. Source papers are summarized only at the level supported by their reported models, and the catalog language avoids translating experimental observations into promises.
The entry is structured for qualified laboratory review. Before publication or experimental comparison, product-specific records should resolve identity, physical form, component definition where applicable, and the relationship between the nominal label amount and any measured result. Until then, uncertainty is retained as part of the product record rather than replaced with assumptions. Each experiment should record the actual lot, reference standard, assay matrix, controls, instrument method, and acceptance criteria needed for reproducible interpretation.
Research Material Profile
Tesamorelin 20mg/vial, 10 vials Research
Defined-population controlled research
A pooled analysis of controlled tesamorelin studies examined a characterized investigational material in a specifically enrolled human population. Researchers evaluated prespecified growth-hormone-axis, imaging, and metabolic measures under a formal protocol. This publication provides historical research context for the named molecule, but it is not evidence that an RUO catalog lot has the same sequence, formulation, content, or analytical profile. Population criteria, protocol controls, measurement methods, and statistical plans are essential parts of the report and prevent broad extrapolation. The paper should be read as an example of how endpoints were operationalized for a defined study material. It does not validate the 20 mg label, the ten-vial pack, or the 200 mg arithmetic total. No procedural or clinical guidance is derived from it here. Interpretation should remain linked to the reported methods, defined comparators, and confirmed test-article identity rather than the shared catalog name. (PubMed 20554713).
Imaging and laboratory endpoints
A randomized study reported metabolic and imaging endpoints in another defined population using study-controlled tesamorelin material. The relevance to an RUO listing is limited to molecule-specific research history and the types of measurements investigators selected. It does not transfer clinical-grade identity, manufacturing controls, formulation, or study oversight to a commercial research vial. Even where the displayed molecule name matches, exact test-article provenance remains a separate question. Researchers evaluating this pack would need direct lot documentation and independently chosen controls before comparing laboratory observations with a published dataset. Pack arithmetic describes quantity on the listing; it does not show analytical content or study comparability. Interpretation should remain linked to the reported methods, defined comparators, and confirmed test-article identity rather than the shared catalog name. (PubMed 23015655).
Model boundaries and catalog interpretation
A further randomized clinical investigation used imaging endpoints and a characterized tesamorelin preparation in a prespecified setting. Such evidence is highly context dependent: enrollment criteria, comparator structure, assay calibration, and analysis choices constrain the conclusions. On a research catalog page, this source may establish that tesamorelin has been examined with those methods, but it cannot be converted into an outcome promise or a statement about this Lobo lot. The listing remains an RUO pack whose exact molecular and analytical attributes await product-specific documentation. The ten-vial format is a commercial configuration, not a replication of any paper's test article. A qualified investigator should distinguish literature identity, catalog identity, and lot identity as three separate layers when planning any laboratory comparison. Interpretation should remain linked to the reported methods, defined comparators, and confirmed test-article identity rather than the shared catalog name. (PubMed 25038357).
Evidence Boundaries
The cited literature supports only the exact molecule or ingredient, model, and endpoint described in each source. It does not verify this Lobo lot, establish equivalence to another seller's material, or convert a nominal catalog amount into measured content. Cell, biochemical, microbial, ex vivo, animal, and controlled human research are not interchangeable evidence categories. Where a blend is involved, single-ingredient papers do not establish the fixed formulation, component ratio, interaction, compatibility, stability, combined performance, or combined safety. Where a fragment, probe, analogue, or related strength is involved, that distinction remains explicit. No unreported identity, sequence, termini, counterion, purity, sterility, endotoxin status, residual-solvent result, or other analytical attribute is inferred. The listing supplies research context only and includes no clinical guidance, procedural directions, or expected outcome.
Tesamorelin 20mg/vial, 10 vials References
8 curated medical and scientific references used for identity, mechanism, model, and assay context.
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.
Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of clinical endocrinology and metabolism. 2010;95(9):4291-304. doi:10.1210/jc.2010-0490.
Tesamorelin controlled-study evidence · Pooled phase 3 randomized placebo-controlled studies and extensions in adults with HIV-associated abdominal fat accumulation
View research source - Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.
Makimura H, Feldpausch MN, Rope AM, et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. The Journal of clinical endocrinology and metabolism. 2012;97(12):4769-79. doi:10.1210/jc.2012-2794.
Tesamorelin controlled physiology study · Randomized placebo-controlled study in adults with obesity and reduced GH secretion
View research source - Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.
Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-9. doi:10.1001/jama.2014.8334.
Tesamorelin randomized clinical study · Adults with HIV and abdominal fat accumulation assessed by imaging and laboratory endpoints
View research source - Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. Journal of acquired immune deficiency syndromes (1999). 2010;53(3):311-22. doi:10.1097/QAI.0b013e3181cbdaff.
Tesamorelin randomized study with extension · Adults with HIV-associated abdominal fat accumulation
View research source - Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.
Falutz J, Allas S, Mamputu JC, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS (London, England). 2008;22(14):1719-28. doi:10.1097/QAD.0b013e32830a5058.
Tesamorelin long-term controlled-study evidence · Adults with HIV-associated abdominal fat accumulation in extended controlled observation
View research source - Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.
Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. The lancet. HIV. 2019;6(12):e821-e830. doi:10.1016/S2352-3018(19)30338-8.
Tesamorelin multicenter randomized study · Adults with HIV-associated nonalcoholic fatty liver disease
View research source - Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.
González-Sales M, Barrière O, Tremblay PO, et al. Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clinical pharmacokinetics. 2015;54(3):285-94. doi:10.1007/s40262-014-0202-x.
Tesamorelin pharmacokinetic analysis · Population pharmacokinetic modeling from healthy subjects and adults with HIV
View research source - Tesamorelin improves fat quality independent of changes in fat quantity.
Lake JE, La K, Erlandson KM, et al. Tesamorelin improves fat quality independent of changes in fat quantity. AIDS (London, England). 2021;35(9):1395-1402. doi:10.1097/QAD.0000000000002897.
Tesamorelin tissue-imaging substudy · Adults with HIV and abdominal obesity; adipose imaging and tissue-quality measurements
View research source